Gilder Gagnon Howe & Co’s Cytokinetics CYTK Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21.8M	Sell	330,989 -54,831	-14%	-$3.48M	0.26%	84
2025 Q4	$24.5M	Sell	385,820 -3,235	-0.8%	-$201K	0.26%	86
2025 Q3	$21.4M	Buy	389,055 +197,940	+104%	+$8.15M	0.22%	89
2025 Q2	$6.31M	Buy	191,115 +176,253	+1,186%	+$6.13M	0.07%	131
2025 Q1	$597K	Buy	14,862 +2,970	+25%	+$136K	0.01%	207
2024 Q4	$559K	Sell	11,892 -1,663	-12%	-$86.4K	0.01%	229
2024 Q3	$716K	Sell	13,555 -275	-2%	-$15.3K	0.01%	222
2024 Q2	$749K	Sell	13,830 -221	-2%	-$13.3K	0.01%	216
2024 Q1	$985K	Sell	14,051 -12,294	-47%	-$951K	0.01%	209
2023 Q4	$2.2M	Sell	26,345 -188	-0.7%	-$6.81K	0.03%	175
2023 Q3	$782K	Buy	26,533 +69	+0.3%	+$2.3K	0.01%	219
2023 Q2	$863K	Sell	26,464 -373	-1%	-$13.8K	0.01%	232
2023 Q1	$944K	Sell	26,837 -483	-2%	-$19.7K	0.02%	198
2022 Q4	$1.25M	Buy	27,320 +1,485	+6%	+$63.9K	0.02%	191
2022 Q3	$1.25M	Buy	+25,835	New	+$1.24M	0.02%	190

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Gilder Gagnon Howe & Co's CYTK Position: Q1 2026 in Review

Gilder Gagnon Howe & Co reduced its Cytokinetics (CYTK) stake by 14% in Q1 2026, selling an estimated $3.48M and leaving 330,989 shares worth $21.8M. The position accounts for 0.26% of the portfolio, ranked #84.

Gilder Gagnon Howe & Co first reported a position in CYTK in Q3 2022 and has held it in 15 quarters since. The position peaked at $24.5M in Q4 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Gilder Gagnon Howe & Co held 330,989 shares of Cytokinetics worth $21.8M as of Q1 2026.
Gilder Gagnon Howe & Co sold 54,831 Cytokinetics shares in Q1 2026, an estimated $3.48M.
Cytokinetics made up 0.26% of Gilder Gagnon Howe & Co's portfolio in Q1 2026, its #84 holding.
Gilder Gagnon Howe & Co first reported a position in Cytokinetics in Q3 2022 and has held it in 15 quarters since.
Gilder Gagnon Howe & Co's Cytokinetics position peaked at $24.5M in Q4 2025.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2026, filed 15 May 2026.